Skip to main content

Advertisement

SpringerLink
Log in

Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with huge goitrous Hashimoto’s thyroiditis

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

The serum free triiodothyronine (FT3)/free thyroxine (FT4) ratio in patients with huge goitrous Hashimoto’s thyroiditis (HG-HT) is relatively high. We investigated the cause of high FT3/FT4 ratios.

Methods

We measured the serum FT3, FT4, and thyrotropin (TSH) levels of seven patients with HG-HT who had undergone a total thyroidectomy. Eleven patients with papillary thyroid carcinoma served as controls. The activities and mRNA levels of type 1 and type 2 iodothyronine deiodinases (D1 and D2, respectively) were measured in the thyroid tissues of HG-HT and perinodular thyroid tissues of papillary thyroid carcinoma.

Results

The TSH levels in the HG-HT group were not significantly different from those of the controls. The FT4 levels in the HG-HT group were significantly lower than those of the controls, whereas the FT3 levels and FT3/FT4 ratios were significantly higher in the HG-HT group. The FT3/FT4 ratios in the HG-HT group who had undergone total thyroidectomy and received levothyroxine therapy decreased significantly to normal values. Both the D1 and D2 activities in the thyroid tissues of the HG-HT patients were significantly higher than those of the controls. However, the mRNA levels of both D1 and D2 in the HG-HT patients’ thyroid tissues were comparable to those of the controls. Interestingly, there were significant correlations between the HG-HT patients’ D1 and D2 activities, and their thyroid gland volume or their FT3/FT4 ratios.

Conclusions

Our results indicate that increased thyroidal D1 and D2 activities may be responsible for the higher serum FT3/FT4 ratio in patients with HG-HT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. P.R. Larsen, J.E. Silva, M.M. Kaplan, Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr. Rev. 2(1), 87–102 (1981)

    Article  CAS  PubMed  Google Scholar 

  2. D.L. St. Germain, V.A. Galton, The deiodinase family of selenoproteins. Thyroid 7(4), 655–668 (1997)

    Article  Google Scholar 

  3. A.C. Bianco, D. Salvatore, B. Gereben, M.J. Berry, P.R. Larsen, Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 23(1), 38–89 (2002)

    Article  CAS  PubMed  Google Scholar 

  4. G.G.J.M. Kuiper, M.H.A. Kester, R.P. Peeters, T.J. Visser, Biochemical mechanisms of thyroid hormone deiodination. Thyroid 15(8), 787–798 (2005)

    Article  CAS  PubMed  Google Scholar 

  5. D. Salvatore, H. Tu, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J. Clin. Invest. 98(4), 962–968 (1996)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. P. Laurberg, H. Vestergaard, S. Nielsen, S.E. Christensen, T. Seefeldt, K. Helleberg, K.M. Pedersen, Source of circulating 3,5,3’-triiodothyronine in hyperthyroidism estimated after blocking type 1 and type 2 iodothyronine deiodinses. J. Clin. Endocrinol. Metab. 92(6), 2149–2156 (2007)

    Article  CAS  PubMed  Google Scholar 

  7. B.W. Kim, G.H. Daniels, B.J. Harrison, A. Price, J.W. Harney, P.R. Larsen, A.P. Weetman, Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J. Clin. Endocrinol. Metab. 88(2), 594–598 (2003)

    Article  CAS  PubMed  Google Scholar 

  8. A.P. Weetman, C.A. Shepherdley, P. Mansell, C.S. Ubhi, T.J. Visser, Thyroid over-expression of type 1 and type 2 deiodinase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment. Eur. J. Endocrinol. 149(5), 443–447 (2003)

    Article  CAS  PubMed  Google Scholar 

  9. Y. Kanou, A. Hishinuma, K. Tsunekawa, K. Seki, Y. Mizuno, H. Fujisawa, T. Imai, Y. Miura, T. Nagasaka, C. Yamada, T. Ieiri, M. Murakami, Y. Murata, Thyroglobulin gene mutations producing defective intracellular transport of thyroglobulin are associated with increased type 2 iodothyronine deiodinase activity. J. Clin. Endocrinol. Metab. 92(4), 1451–1457 (2007)

    Article  CAS  PubMed  Google Scholar 

  10. F.S. Celi, G. Coppotelli, A. Chidakel, M. Kelly, B.A. Brillante, T. Shawker, N. Cherman, P.P. Feuillan, M.T. Collins, The role of type 1 and type 2 5’-deiodinase in the pathophysiology of the 3,5,3’-triiodothyronine toxicosis of McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 93(6), 2383–2389 (2008)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. M. Ito, N. Toyoda, E. Nomura, Y. Takamura, N. Amino, T. Iwasaka, J. Takamatsu, A. Miyauchi, M. Nishikawa, Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3’-triiodothyronine-predominant Graves’ disease. Eur. J. Endocrinol. 164(1), 95–100 (2011)

    Article  CAS  PubMed  Google Scholar 

  12. N. Toyoda, E. Nomura, M. Ito, A. Harada, K. Nishimura, C. Ukita, T. Iwasaka, S. Kubota, A. Miyauchi, M. Nishikawa, Type 2 iodothyronine deiodinase activity is highly expressed in the large goiter with Hashimoto’s thyroiditis. Program of the 14th International Congress of Endocrinology. The Japan Endocrine Society (Kyoto, Japan, 2010), p S478, (Abstract P4-16-2)

  13. Y. Murakami, J. Takamatsu, S. Sakane, K. Kuma, N. Ohsawa, Changes in thyroid volume in response to radioactive iodine for Graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J. Clin. Endocrinol. Metab. 81(9), 3257–3260 (1996)

    CAS  PubMed  Google Scholar 

  14. D. Bellabarba, R.E. Peterson, K. Sterling, An improved method for chromatography of iodothyronines. J. Clin. Endocrinol. Metab. 28(2), 305–307 (1968)

    Article  CAS  PubMed  Google Scholar 

  15. M. Ito, A. Miyauchi, S. Morita, T. Kudo, E. Nishihara, M. Kihara, Y. Takamura, Y. Ito, K. Kobayashi, A. Miya, S. Kubota, N. Amino, TSH-suppresive dose of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur. J. Endocrinol. 167(3), 373–378 (2012)

    Article  CAS  PubMed  Google Scholar 

  16. B. Gereben, C. Goncalves, J.W. Harney, P.R. Larsen, A.C. Bianco, Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol. Endocrinol. 14(11), 1697–1708 (2000)

    Article  CAS  PubMed  Google Scholar 

  17. Y. Imai, N. Toyoda, A. Maeda, T. Kadobayashi, F. Wang, K. Kuma, M. Nishikawa, T. Iwasaka, Type 2 iodothyronine deiodinase expression is upregulated by the protein kinase A-dependent pathway and is downregulated by the protein kinase C-dependent pathway in cultured human thyroid cells. Thyroid 11(10), 899–907 (2001)

    Article  CAS  PubMed  Google Scholar 

  18. D.L. Germain, Dual mechanisms of regulation of type I iodothyronine 5’-deiodinase in the rat kidney, liver, and thyroid gland. Implic. Treat. hyperthyroidism Radiogr. Contrast Agents J. Clin. Invest. 81(5), 1476–1484 (1988)

    Google Scholar 

  19. A.P. Weetman, in Werner & Ingbar’s The Thyroid, ed. by L.E. Braverman, D.S. Cooper, D.S. (eds.) 10th edn. (Lippincott Williams & Willkins, Philadelphia, 2013), pp. 525–535

  20. A.L. Maia, B.W. Kim, S.A. Huang, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J. Clin. Invest. 115(9), 2524–2533 (2005)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by the Smoking Research Foundation of Japan Grant Number FP01606073.

Author information

Authors and Affiliations

  1. Internal Medicine II, Kansai Medical University, Hirakata, Osaka, 573-1010, Japan

    Azusa Harada, Emiko Nomura, Kumiko Nishimura, Ichiro Shiojima & Nagaoki Toyoda

  2. Kuma Hospital, Kobe, Hyogo, 650-0011, Japan

    Mitsuru Ito, Hiroshi Yoshida, Akira Miyauchi & Mitsushige Nishikawa

Authors
  1. Azusa Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emiko Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kumiko Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mitsuru Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Miyauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mitsushige Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ichiro Shiojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nagaoki Toyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nagaoki Toyoda.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Ethics Committee at Kuma Hospital, and all patients gave informed consent for their materials to be used and for their data to be published. This study was conducted in accordance with the principles of the Declaration of Helsinki.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harada, A., Nomura, E., Nishimura, K. et al. Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with huge goitrous Hashimoto’s thyroiditis. Endocrine 64, 584–590 (2019). https://doi.org/10.1007/s12020-019-01855-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-019-01855-7

Keywords

Search

Navigation